The new-look ELANA device from AMT Medical could simplify CABG procedures and help improve patient access to minimally invasive and robotic surgical techniques. The new-look ELANA device from AMT Medical could simplify CABG procedures and help improve patient access to minimally invasive and robotic surgical techniques. | | |
|
Ami B. Bhatt, MD, a veteran cardiologist and digital health specialist, stepped down as the American College of Cardiology's chief innovation officer to accept this new role. Ami B. Bhatt, MD, a veteran cardiologist and digital health specialist, stepped down as the American College of Cardiology's chief innovation officer to accept this new role. | | |
|
High-volume hospitals are often associated with better TAVR outcomes. The team behind this new study wanted to see if a similar trend was seen with FTR rates as well. High-volume hospitals are often associated with better TAVR outcomes. The team behind this new study wanted to see if a similar trend was seen with FTR rates as well. | | |
|
An investigational drug therapy from Affinia Therapeutics has secured the FDA's orphan drug designation. This means the company now has access to certain benefits, including tax credits and fee exemptions, as it works toward approval. An investigational drug therapy from Affinia Therapeutics has secured the FDA's orphan drug designation. This means the company now has access to certain benefits, including tax credits and fee exemptions, as it works toward approval. | | |
|
|
More than 750,000 devices are included in the new Class II recall. At this time, however, no devices need to be returned to the manufacturer. More than 750,000 devices are included in the new Class II recall. At this time, however, no devices need to be returned to the manufacturer. | | |
|
Novo Nordisk filed a lawsuit claiming Eli Lilly ran “false and materially misleading” advertisements that ignore recent data. According to Lilly, though, its message is "truthful" and "grounded in the most direct scientific evidence available." Novo Nordisk filed a lawsuit claiming Eli Lilly ran “false and materially misleading” advertisements that ignore recent data. According to Lilly, though, its message is "truthful" and "grounded in the most direct scientific evidence available." | | |
|
Long-term TAVR outcomes were comparable. When tracking 30-day data, however, researchers found that hospital readmission was much less common for patients treated with regional anesthesia or moderate sedation. Long-term TAVR outcomes were comparable. When tracking 30-day data, however, researchers found that hospital readmission was much less common for patients treated with regional anesthesia or moderate sedation. | | |
|
|
Many cardiologists are earning more in 2026 than they did in 2025. However, there is a fear that compensation and wRVUs can only climb so far in this current healthcare environment before things start to stall. Many cardiologists are earning more in 2026 than they did in 2025. However, there is a fear that compensation and wRVUs can only climb so far in this current healthcare environment before things start to stall. | | |
|
Thousands of procedure kits used by cardiologists and cardiac surgeons are impacted by the new Class II recall. Thousands of procedure kits used by cardiologists and cardiac surgeons are impacted by the new Class II recall. | | |
|
When should heart patients be taking daily aspirin? That's just one of the many questions explored in a new scientific statement. When should heart patients be taking daily aspirin? That's just one of the many questions explored in a new scientific statement. | | |
|
|
Addressing these gaps will require more inclusive risk prediction models and system-level interventions such as EMR optimization and provider education to improve uptake. Addressing these gaps will require more inclusive risk prediction models and system-level interventions such as EMR optimization and provider education to improve uptake. | | |
|
That equates to $16.25 per share, a 6% premium over the current market price. The deal will expand Tempus’ molecular residual disease test offerings, allowing the company to better support cancer patients. That equates to $16.25 per share, a 6% premium over the current market price. The deal will expand Tempus’ molecular residual disease test offerings, allowing the company to better support cancer patients. | | |
|
